A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16000
- Registration Number
- NCT05754957
- Locations
- 🇺🇸
Northwest Heart Clinical Research, LLC., Tomball, Texas, United States
🇮🇳Lisie Hospital, Cochin, India
🇮🇳Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, India
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT05742594
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1135
- Registration Number
- NCT05714202
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇧🇷Liga Paranaense de Combate ao Cancer, Curitiba, Brazil
🇧🇷Hospital Regional do Cancer - Hospital de Esperança, Presidente Prudente, Brazil
A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-77242113
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT05703841
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- Conditions
- Ischemic Stroke; Ischemic Attack, Transient
- Interventions
- Drug: PlaceboDrug: Milvexian
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15000
- Registration Number
- NCT05702034
- Locations
- 🇺🇸
Neurology Center of North Orange County, Fullerton, California, United States
🇺🇸Mission Hospital Regional Medical Center, Mission Viejo, California, United States
🇺🇸McGovern Medical School UT Physicians Neurosurgery Texas Medical Center, Houston, Texas, United States
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT05663866
- Locations
- 🇫🇷
Hopital Europeen Georges-Pompidou, Paris, France
🇫🇷CHU Rouen Hopital Charles Nicolle, Rouen, France
🇰🇷Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness
- Conditions
- Acute Respiratory Viral Infection
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT05661604
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇨🇦Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Fred Hutchinson Research Center, Seattle, Washington, United States
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT05653427
- Locations
- 🇨🇳
The First Hospital of Jilin University, Chang Chun Shi, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Zhejiang University First Hospital, Hang Zhou Shi, China
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Conditions
- Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
- Interventions
- Drug: JNJ-79635322
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 195
- Registration Number
- NCT05652335
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇪🇸
Institut Catala d Oncologia L Hospitalet, Hospitalet de Llobregat, Spain
🇺🇸Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States